Company Performance Metrics
- Michael Davis: Founder
Kerry Ressler: Founder
Extinction Pharmaceuticals, Inc. is a drug development company with a proprietary and revolutionary therapeutic approach (i.e., administering D-cycloserine in conjunction with therapy) for treating anxiety disorders and other afflictions that can benefit from traditional talk therapy treatments. Fundamentally, their drug works by consolidating the
learning from a therapy session, thereby making therapy sessions more efficient. This effect has been demonstrated in placebo-controlled, double-blind human clinical trials for panic disorder, social anxiety disorder, obsessive-compulsive disorder, and simple phobia, and is currently being tested in investigator-initiated clinical trials for addiction, autism, stroke recovery, and other conditions.
